Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Copper peptides (GHK-Cu)

Also known as: GHK-Cu, copper tripeptide, glycyl-L-histidyl-L-lysine copper complex

Copper peptides are short chains of amino acids bound to copper. The best-known skincare example is GHK-Cu, studied in cosmetic products for skin appearance and in laboratory and wound-care research. Evidence and intended use differ between the finished products.

In plain English — Copper peptides are small protein building blocks joined to copper and used in some skincare products. Small studies of particular products suggest they may improve the appearance of facial lines. Those results belong to the products tested, rather than every serum containing a copper peptide.

Evidence status

Emerging

Small human studies support some finished-product appearance outcomes, with important design and commercial-interest limitations. Laboratory activity, cosmetic facial outcomes and wound-care results answer different questions; they do not establish an interchangeable ingredient-class effect.

What copper peptides are, and the types available#

GHK-Cu combines copper with glycyl-histidyl-lysine, a peptide made from three amino acids. Research examines both its biological activity and its delivery in finished products. The wider peptides entry explains the ingredient family; the subject here is copper complexes, particularly GHK-Cu.[1, 2]

The literature includes a nanocarrier serum, a cream combining GHK-Cu with a microbial ferment extract, and wound-care preparations. These are distinct formulations and settings, not interchangeable versions of one clinically standardised treatment. An older ulcer paper identifies a tripeptide-copper complex without specifying its sequence in the accessible abstract.[1, 3]i[5]

Use of copper peptides in aesthetic practice#

The cosmetic role is principally assessment of skin appearance: facial lines, surface quality and the suitability of a particular moisturising product. The available facial studies support a product-specific discussion of possible benefit and timescale, rather than a promise of structural rejuvenation for an ingredient name.[1, 3]i

In Great Britain, professional-use cosmetics fall within cosmetic-product requirements, including a Responsible Person and safety assessment. Product claims need supporting evidence. This is a product-supply framework, not a statement about who may perform an aesthetic procedure.[7]

Contraindications and cautions#

A previous reaction to a constituent is relevant to product selection. Itchy, blistered, cracked or actively inflamed skin warrants assessment before adding a new cosmetic; avoidance of an identified dermatitis trigger takes precedence over its advertised benefits.[8, 9]

The intended use and exposure covered by the product’s safety assessment matter, particularly around procedures that alter the skin surface. A leave-on serum should not be reassigned to injection, needling-assisted delivery or an open wound simply because it contains a molecule studied in those areas. Suitability must be established for the actual product and use.[6, 7]i

This review did not locate a pregnancy-specific clinical safety study of topical GHK-Cu. That gap does not demonstrate harm, but it prevents a pregnancy-safety assurance based on these studies alone. Product-specific advice should be checked with the client’s maternity or prescribing clinician.[no source found]

Clinical uses and the evidence behind them#

Facial appearance

Badenhorst and colleagues studied a nanocarrier GHK-Cu serum over eight weeks in 40 women aged 40–65; 39 completed. Instrument measurements near the outer eye favoured the serum over its control for wrinkle depth and volume. This is a positive product result, with important design limits: comparator groups were randomised, but the active was always applied to the right side, and the control omitted both GHK-Cu and its carrier. Snowberry and Callaghan Innovation funded the work; the paper states that Snowberry did not conduct or interpret the analysis.[1]

Wang and colleagues enrolled 32 Asian adults, mostly women, aged 30–57; 30 completed 56 days using a cream containing 5% ferment extract and 0.2% GHK-Cu. Several appearance and hydration measures improved from baseline. There was no clinical control group, so the ingredient’s separate contribution cannot be determined. All authors worked for Shanghai Chicmax Cosmetic Co., Ltd, despite declarations of no conflicts and no outside funding.[3]

Post-resurfacing and wound care

In Miller’s randomised study, 13 people completed follow-up after circumoral CO2 laser resurfacing. At 12 weeks, the copper-peptide regimen offered no objective advantage for erythema, wrinkles or overall skin quality, although patient ratings favoured it. The small sample limits precision; funding details were not available in the retrieved abstract.[4]

In a separate venous-ulcer trial, a tripeptide-copper cream did not outperform vehicle among 86 evaluable completers. Treatment duration and the exact peptide sequence were not stated in the retrieved abstract, and funding was not established. This disease-specific result belongs in wound-care interpretation, not a verdict on all facial cosmetics.[5]

Selecting copper peptides#

Selection begins with the actual product: its named ingredients, intended use, claims, tolerability information and supporting human study. A trial should match the question being asked — facial appearance, moisturisation or a defined clinical recovery outcome — and the formulation being considered.[1, 3]i[7]

Delivery systems and co-ingredients deserve attention because they are part of the intervention. A serum studied with a nanocarrier and a cream studied with a ferment extract provide different evidence. A useful supplier discussion concerns the whole formula, rather than ranking products by the copper-peptide percentage alone.[1, 3]i

Adverse effects and their management#

In the 2016 facial study, one participant developed a minor reaction on both treated sides, stopped participation and recovered without medical treatment. This does not identify copper peptide as the cause or establish a reliable population-wide adverse-event rate.[1, 8]i

For a suspected product reaction, stop exposure to the suspected trigger and arrange appropriate assessment. Contact dermatitis may involve itching, blistering, dryness and cracking; visible inflammation may look different across skin tones. Persistent, recurrent or severe symptoms require medical review.[8, 9]

Referral and scope boundaries#

A suspected leg ulcer requires GP assessment and specialist care to identify and address its cause. The existence of copper-complex wound research does not turn an ulcer into a cosmetic-skincare problem. Post-resurfacing concerns similarly belong with the responsible treating clinician and their care plan.[4][8, 9]

For ordinary cosmetic selection, the relevant professional task is matching product information to the client’s skin and intended use. Product safety documentation and cosmetic claims are distinct from clinical competence or authorisation to undertake procedures.[7]

Mechanism of action#

The biological interest centres on extracellular-matrix regulation. In cultured adult human dermal fibroblasts, GHK-Cu altered expression of matrix metalloproteinases and their inhibitors — systems involved in matrix turnover — and increased collagen and elastin production at 96 hours. These were laboratory experiments in cells, funded within the same Snowberry/Callaghan-supported paper as the facial study.[2]

Delivery is another research strand. Li and colleagues measured permeation over nine hours through ex-vivo human skin, finding greater delivery after polymeric microneedle pretreatment than through intact skin in that experimental system. The result concerns that delivery model and formulation.[6]

Commonly misstated claims#

“GHK-Cu removes 55.8% of wrinkles”

Claim heard: A trial showed wrinkles reduced by 55.8% from their starting point.

Literature finding:The 2016 paper’s 55.8% figure describes its comparison with control. In that comparison group, mean wrinkle-volume changes from baseline were −24.1% (SD 8.6) for active and −15.0% (SD 5.2) for control. These are different denominators and quantities.[1]

Supported statement:The tested product improved measured wrinkle volume more than its control; the headline percentage is not the proportion of a person’s wrinkles that disappeared.[1]

“The facial trial measured new collagen in people’s skin”

Claim heard: The paper directly demonstrated facial collagen production in its volunteers.

Literature finding: Its collagen experiment used cultured human fibroblasts; the separate volunteer study measured surface wrinkle parameters. No participant collagen measurement established the proposed link between those two parts.[1][2]

Supported statement: The paper provides laboratory matrix findings and a separate cosmetic appearance result, not a human biopsy demonstration of new facial collagen.[2]

“The delivery study established clinical safety”

Claim heard: Increased delivery through microneedled skin was shown to be safe in a human treatment trial.

Literature finding:The delivery experiment used ex-vivo human skin; the safety assessments used cellular and porcine models. The authors’ favourable safety conclusion belongs to those models.[6]

Supported statement: The study supports further investigation of a delivery approach; it is not a clinical safety trial in people receiving cosmetic aftercare.[6]

Areas of remaining uncertainty#

  • Reproducibility: Independent replication with randomised treatment side and controls separating ingredient from carrier would clarify the benefit attributable to GHK-Cu. Until then, discuss the measured result as a finding for the tested product.[1, 3]i
  • Durability: Longer follow-up after stopping treatment is needed before promising persistent improvement or a maintenance schedule.[1, 3]i
  • Tolerability across users: Broader populations and longer observation would better inform uncommon reactions and repeated use; the present studies do not supply a reliable general-user adverse-event rate.[1, 3]i

Frequently asked questions#

What does GHK stand for?

Glycyl-histidyl-lysine: the three amino acids forming the peptide. “Cu” indicates its copper complex.[1, 2]

What information is useful when comparing two products?

The finished formula, intended use and study endpoint are more informative together than an ingredient name alone. Evidence for the specific product is particularly useful when its delivery system or combination ingredients differ.[1, 3]i[7]

Who should assess an ongoing reaction?

A clinician should assess persistent, recurrent or severe dermatitis, especially when the trigger is unclear or initial avoidance has not resolved it.[8, 9]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science. 2016;4(3):166. doi:10.4172/2329-8847.1000166. Clinical component.Tier 3Supports: Eight-week split-face product study in 40 women aged 40–65, with 39 completers; comparator-group allocation was randomised but the active product was always applied to the right side. Objective periorbital wrinkle measurements and tolerability.Funding / interest: Snowberry New Zealand Ltd and Callaghan Innovation grant ENDU1101. Snowberry supplied active and control products. Paper states Snowberry had no involvement in collection, analysis, interpretation, submission decision or writing; independent statistical analysis was acknowledged.
  2. Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science. 2016;4(3):166. doi:10.4172/2329-8847.1000166. Cultured-cell component of the same paper as source 1.In vitroTier 3Supports: Cultured adult human dermal fibroblasts: collagen/elastin protein production and MMP/TIMP expression. This is laboratory work, not a second independent clinical study.Funding / interest: Same paper and commercial disclosure as source 1: Snowberry New Zealand Ltd and Callaghan Innovation grant ENDU1101; the paper states no Snowberry involvement in collection, analysis, interpretation, submission decision or writing.
  3. Wang J, Tao K, Huang H, Chang H. Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu. Skin Research and Technology. 2026;32(8):e70360. doi:10.1111/srt.70360. PMID:42573538.Tier 3Supports: Uncontrolled 56-day facial study of a 5% ferment-extract plus 0.2% GHK-Cu cream; 32 Asian adults enrolled, 30 completed. Appearance and biophysical outcomes were compared with baseline, not a clinical vehicle group.Funding / interest: All authors affiliated with the Global R&D Center of Shanghai Chicmax Cosmetic Co., Ltd. The paper declares no conflicts and no funding from outside organisations; this remains manufacturer-authored research.
  4. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006;8(4):252–259. doi:10.1001/archfaci.8.4.252. PMID:16847171.Tier 2Supports: Randomised post-circumoral-CO2-resurfacing study with 13 completers and 12-week assessment: no objective advantage in erythema, wrinkles or overall skin quality; patient-reported skin quality favoured the copper-peptide regimen.Funding / interest: Named sponsor and conflict disclosures were not available in the personally retrieved abstract. PubMed's research-support indexing does not establish independence.
  5. Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery. 1992;16(2):251–257. doi:10.1067/mva.1992.37086. PMID:1495150.Tier 2Supports: Trial with 86 evaluable completers comparing silver sulfadiazine, a tripeptide-copper cream and vehicle on venous stasis ulcers. Copper cream did not outperform vehicle; abstract does not identify the peptide sequence or treatment duration.Funding / interest: Sponsor and conflicts were not established from the personally retrieved official abstract.
  6. Li H, Low YS, Chong HP, et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharmaceutical Research. 2015;32(8):2678–2689. doi:10.1007/s11095-015-1652-z. PMID:25690343.Ex vivoTier 3Supports: Ex-vivo human-skin permeation after polymeric microneedle pretreatment, compared with intact skin, over nine hours. Separate cellular and porcine models were used for safety evaluation.Funding / interest: The retrieved official abstract identifies a university affiliation; sponsor and full conflict declaration were not available. University affiliation is not treated as evidence of independent funding.
  7. Office for Product Safety and Standards. Making cosmetic products available to consumers in Great Britain. Published 4 October 2021. Accessed 16 September 2026.Tier 1Supports: Great Britain cosmetic-product requirements: Responsible Person, safety assessment, intended use/exposure, product information, labelling and evidence supporting claimed effects. This is not a practitioner-licensing source.Funding / interest: UK government regulatory guidance; no product sponsor.
  8. NHS. Contact dermatitis. Reviewed 3 May 2023. Accessed 16 September 2026.Tier 4Supports: Recognition of irritant/allergic skin reactions, avoidance of identified triggers and assessment of persistent, recurrent or severe dermatitis.Funding / interest: NHS patient information; no product sponsor stated. Displayed next-review date had passed.
  9. NHS. Venous leg ulcer. Reviewed 16 November 2022. Accessed 16 September 2026.Tier 4Supports: A suspected leg ulcer requires GP assessment and specialist treatment, including investigation of its cause.Funding / interest: NHS patient information; no product sponsor stated. Displayed next-review date had passed.